Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 5460302, 16 pages
http://dx.doi.org/10.1155/2016/5460302
Review Article

Natural Compounds as Regulators of NLRP3 Inflammasome-Mediated IL-1β Production

1Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
2Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

Received 9 May 2016; Revised 18 July 2016; Accepted 11 August 2016

Academic Editor: Alex Kleinjan

Copyright © 2016 József Tőzsér and Szilvia Benkő. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

IL-1β is one of the main proinflammatory cytokines that regulates a broad range of immune responses and also participates in several physiological processes. The canonical production of IL-1β requires multiprotein complexes called inflammasomes. One of the most intensively studied inflammasome complexes is the NLRP3 inflammasome. Its activation requires two signals: one signal “primes” the cells and induces the expression of NLRP3 and pro-IL-1β, while the other signal leads to the assembly and activation of the complex. Several stimuli were reported to function as the second signal including reactive oxygen species, lysosomal rupture, or cytosolic ion perturbation. Despite very intensive studies, the precise function and regulation of the NLRP3 inflammasome are still not clear. However, many chronic inflammatory diseases are related to the overproduction of IL-1β that is mediated via the NLRP3 inflammasome. In this review, we aimed to provide an overview of studies that demonstrated the effect of plant-derived natural compounds on NLRP3 inflammasome-mediated IL-1β production. Although many of these studies lack the mechanistic explanation of their action, these compounds may be considered as complementary supplements in the treatment of chronic inflammatory diseases, consumed as preventive agents, and may also be considered as molecular tools to study NLRP3 function.

1. Introduction

Inflammation is an important host response triggered by invading pathogens or damaged tissues, a response that is aimed at diluting or destroying the pathogens or isolating the involved site. Moderate inflammatory response contributes to the host defense by removing pathogens or aiding in the repair of damaged tissue. However, uncontrolled or prolonged inflammation may promote further tissue damage and could lead to serious disorders due to the overproduction of inflammatory cytokines.

Among inflammatory mediators, IL-1β is a master regulatory cytokine, functioning at several levels of immune responses, such as activation of cells to produce other inflammatory cytokines and chemokines, induction of endothelial cells to express cell membrane adhesion molecules, or assisting in the polarization of human Th17 cells [13]. Furthermore, it also participates in a variety of physiological processes, such as the regulation of synaptic plasticity and memory processes, in addition to participating in pain development [47].

The production of IL-1β requires a multiprotein complex called inflammasome. One of the most intensively studied inflammasomes is the NLRP3 inflammasome that contains NLRP3 sensor, ASC adaptor, and caspase-1 protease [8]. The presence of NLRP3 inflammasome has been shown not only in immunocompetent cells but also in cells responsible for various physiological functions, such as muscle cells, neurons, or endocrine cells. Upon stimulation, NLRP3 inflammasome components assemble into large cytoplasmic complexes, and the activation of caspase-1 eventually leads to the maturation and secretion of IL-1β. Besides cytokine production, NLRP3 inflammasome activation may also be accompanied by caspase-1-mediated rapid cell death, which is known as pyroptosis [9].

2. Mechanism of NLRP3 Inflammasome Activation

NLRP3 inflammasome can be activated by a broad range of stimuli that belong either to pathogen-associated molecular patterns (PAMPs) released during viral, bacterial, fungal, or protozoa infection [1013] or to danger-associated molecular patterns (DAMPs) of endogenous or exogenous origin, like extracellular ATP, reactive oxygen species (ROS), cholesterol, monosodium urate (MSU) crystals, amyloid beta (Aβ) plaques, silica, or asbestos [1420] (Figure 1).

Figure 1: Basic mechanisms of NLRP3 inflammasome activation.

Due to the multiple functions of IL-1β, production of this cytokine is tightly regulated, requiring two signals. The first signal, called “priming,” is mediated through PAMPs recognized by specific receptors like TLRs, activating signal transduction pathways that induce the expression of the inflammasome components as well as that of the inactive cytokine precursor pro-IL-1β. Signaling pathways through NFκB, p38, and ERK1 have all been associated with the expression of NLRP3 and pro-IL-1β [2123]. The second signal, provided by DAMPs or PAMPs, leads to the assembly of the inflammasome complex that is followed by activation of caspase-1 and the cleavage and secretion of active IL-1β [24, 25]. Considering the diversity of the second signals sensed by NLRP3, it is highly unlikely that NLRP3 is capable of interacting directly with chemically different activators. It is more likely that NLRP3 senses a general signal that induces the sequential events of inflammasome activation. Several cellular mechanisms were reported as requirements for activation, including intracellular release of oxidized mitochondrial DNA (mtDNA), increased intracellular Ca2+ concentration, decreased intracellular cAMP level, or pore formation by bacterial toxins [2628]. Common cellular events are assumed to be critical for the inflammasome activation, including ROS formation, potassium (K+) efflux, and cathepsin B leakage from lysosomes [29]. However, due to the controversial results published in the field, the precise mechanism that mediates NLRP3 inflammasome activation is still not known. It is conceivable that more than one single requirement needs to be fulfilled, and these requirements may depend on the activating stimuli, also the per se characteristics of the stimulated cell.

2.1. Reactive Oxygen Species

Several NLRP3 inflammasome activating stimuli like nigericin or ATP induce oxidative stress and the production of intracellular ROS [15]. The source of ROS is still unclear, as some of the studies reported the role of NADPH oxidase in ROS generation [30], while other studies proved that mitochondrial dysfunction or ER stress leads to ROS production. As a consequence of mitochondrial dysfunction, oxidized mtDNA is released which can activate NLRP3 inflammasome [26], eventually leading to IL-1β production. It was also shown that, in case of increased cytoplasmic ROS, reduced thioredoxin (TRX) becomes oxidized and dissociates from thioredoxin binding protein (TXNIP) that in turn binds to and activates NLRP3. It was also shown that the expression of TXNIP is upregulated during ER stress, which also induces NLRP3 activation [31]. During oxidative stress, misfolded proteins accumulate, which are sensed by the ER membrane-bound inositol-requiring enzyme 1 (IRE1α) and protein kinase RNA-like endoplasmic reticulum kinase (PERK). In turn, they initiate ER stress response, activate NFκB pathways, and induce the upregulation of TXNIP expression [32]. The role of nuclear factor- (erythroid-derived 2) like 2 (Nrf2) transcription factor-mediated antioxidant signaling pathway has also been reported as a negative regulator of NLRP3 inflammasome, as disruption of Nrf2 leads to increased production of IL-1β [33]. Recent works highlight the importance of metabolic changes such as in glycolysis and oxidative phosphorylation that accompany cell activation and influence ROS production [34, 35]. Moreover, ROS influences signal transduction pathways such as NFκB; thus, besides NLRP3 inflammasome activation, it is also thought to play a role in the “priming” step [36].

2.2. Ion Flux and Perturbation

Perturbation of cytosolic ion concentration, such as K+ and Ca2+, is a common result of several NLRP inflammasome activating stimuli, as many activators were shown to directly induce ion fluxes. Nigericin or the activation of ATP-sensitive P2X7 receptor induces rapid efflux of K+ [3739], and K+ efflux has been proven to act as a common signal to trigger NLRP3 inflammasome activation [40]. Furthermore, several pore forming toxins result in an increased intracellular Ca2+ that triggers NLRP3 activation [41]. Nevertheless, changes in intracellular ion concentration would also stimulate other inflammasome complexes, which argues against ion flux as the exclusive cause for NLRP3 inflammasome activation.

2.3. Lysosomal Rupture and Cathepsin B Release

Destabilization of the acidic lysosomal compartment and release of lysosomal protease cathepsin B into the cytoplasm during phagocytosis of large particles or crystals, such as silica, asbestos, uric acid, or beta-amyloids, have also been implicated in the activation of the NLRP3 inflammasome [42]. Furthermore, phagocytosis could also induce K+ efflux. Additionally, lysosomes contain high concentration of Ca2+, and lysosomal rupture results in the release of Ca2+ into the cytosol, triggering further Ca2+ release from the ER. However, the molecular details and connections of these events are not yet clarified. In conclusion, although NLRP3 inflammasome is the most intensively studied inflammasome complex, it is still unclear which mechanisms are responsible for its activation.

2.4. Mitochondrial Dysfunction

In response to infection or endogenous stimuli, the perturbation of intracellular ROS, K+, or lysosomal stability leads to mitochondrial dysfunction and to the release of mitochondrial DAMPs such as mtDNA, cardiolipin, or dynamin-related protein 1 (Drp1) [43]. It was shown that due to increased mtROS level, released mtDNA is oxidized and activates NLRP3 inflammasome [26]. Cardiolipin is a non-bilayer-forming phospholipid found in bacteria and in the inner mitochondrial membrane of eukaryotes, and its translocation from the inner membrane to the outer membrane was shown to activate NLRP3 inflammasome downstream of mtROS [44]. It was also reported that GTPase Drp1, that is needed for the fragmentation and aggregation of mitochondria, also induces NLRP3 inflammasome activation and IL-1β secretion in response to VSV infection but not to ATP or nigericin [45]. Moreover, mitofusin, an outer mitochondrial GTPase that regulates mitochondrial fusion, was also described as an NLRP3 activator during viral infection [46]. Recently, it was described that the mitochondrial antiviral signaling protein (MAVS) located in the mitochondrial membrane mediating interferon responses also induces NLRP3 inflammasome activation [47]. These reports demonstrate that the mitochondrion is a complex regulator of cytosolic homeostasis and a central platform for NLRP3 inflammasome activation.

2.5. Autophagy

Autophagy is an evolutionarily conserved mechanism to maintain cellular homeostasis by selectively eliminating damaged or aging organelles, microbes, and ubiquitinated proteins, through the formation of autophagosomes and using lysosomal degradation. Lines of evidence show that autophagy suppresses organelle stress-induced activation of NLRP3 inflammasome. Furthermore, it was reported that inducers of autophagy also induce the autophagosomal engulfment of IL-1β and its lysosomal degradation [48]. It was also shown that damaged mitochondria accumulate in autophagy-deficient macrophages that in turn lead to increased intracellular ROS and to the release of mtDNA [49].

2.6. Spatial Location of NLRP3

Originally, it was shown that activated NLRP3 inflammasome localizes to the mitochondria. However, recently, it was described that during inflammasome activation ER-associated NLRP3 colocalizes with the mitochondria-associated ASC to the perinuclear space via a microtubule-mediated organelle transport. It was shown that, upon cell activation, the decreased intracellular NAD+ level leads to the inhibition of sirtuin 2 (SIRT2) deacetylase, resulting in the accumulation of acetylated alfa-tubulin triggering a dynein-dependent transport of mitochondria to the perinuclear region, into the close proximity to the ER [50].

3. NLRP3 Inflammasome and Related Diseases

Understanding the steps and mechanism of NLRP3 inflammasome activation would be of crucial importance for the treatment of several diseases in which the inflammasome complex has been implicated. By producing IL-1β inflammatory cytokine and inducing pyroptosis, the primary function of NLRP3 inflammasome is to protect the host from invading microorganisms [78]. However, nonmicrobial compounds of either endogenous (self-derived) or exogenous (environmental) origin are also effective inducers of NLRP3 inflammasome activation and lead to sterile inflammation, allergic responses, or other forms of inflammation [79]. For example, studies have shown that NLRP3 may be implicated in Alzheimer’s disease, suggesting that misfolded Aβ proteins form aggregates that lead to the activation of NLRP inflammasome [80, 81]. In gout, MSU crystals from purine degradation form deposits in different tissues and specifically activate NLRP3 inflammasome [14]. Environmental particulates such as inhaled asbestos and silica also activate NLRP3 inflammasome, and the high concentration of IL-1β is involved in the development of asbestosis and silicosis, two progressive pulmonary diseases leading to fibrosis [16, 82]. NLRP3 inflammasome has also been related to allergic responses to a variety of allergens, such as aluminum, dust mite, or ragweed pollen; however, the molecular details of these responses are still not clear [8385].

Other studies associated NLRP3 inflammasome function with metabolic syndrome and type 2 diabetes, as NLRP3 deficient mice were protected from high fat diet- (HFT-) induced inflammation, glucose intolerance, insulin resistance, and obesity [86, 87].

The dysregulated production of IL-1β by the NLRP3 inflammasome is the main reason for the development of Cryopyrin-Associated Periodic Syndromes (CAPS) which is caused by a mutation in NLRP3 gene. CAPS is an autoinflammatory disorder rather than an autoimmune one, as symptoms are mediated by the innate immune system, mainly by monocytes and macrophages that produce huge amount of IL-1β. Behcet’s disease (BD) is another chronic autoinflammatory disorder of unknown etiology, and increased IL-1β production has been noted as a central player in the pathogenesis of this disease. Studies demonstrated increased ROS production and, consequently, increased NLRP3 function in these patients, suggesting an important role for NLRP3 inflammasome in mediating cytokine production [88]. In addition to autoinflammatory diseases, NLRP3 inflammasome function has also been implicated in the development of autoimmune diseases like rheumatoid arthritis (RA) [89]. RA is a common inflammatory disease affecting small joints, and our knowledge about its pathogenesis is still incomplete. Nevertheless, elevated levels of IL-1β and high expression of NLRP3 were detected from the serum and synovial tissue as well as in macrophages of RA patients [90].

At present, the role of NLRP3 inflammasome and IL-1β in cancer is highly controversial. The microenvironment of tumors is characterized by an inflammatory milieu that helps tumor survival with growth hormones, endothelial activation, and angiogenesis that leads to metastasis accompanied by immune suppression. IL-1β participates in each of these mechanisms by stimulating the expression of TNFα, MMPs, VEGF, ICAM-1, VCAM, and so forth. Cancer cells, like melanoma or myeloma, as well as tumor-associated macrophages and dendritic cells, were shown to contribute to the IL-1β production that helps survival and growth of tumor cells; furthermore, excessive production of IL-1β can recruit immunosuppressive cells like myeloid-derived suppressors cells (MDSCs) [91]. On the other hand, it was also shown that NLRP3-induced IL-1β production boosts T cell function in patients receiving chemotherapy [92].

The classical medical approach to treating the above-mentioned diseases involves the use of synthetic drugs developed against individual elements of the signaling pathway, the IL-1β cytokine, or the IL-1β receptor, as reviewed in Ozaki et al., 2015 [93]. However, today, in the health-cautious life era, the use of botanical and natural compounds has gained popularity. While a few decades ago the use of natural compounds was based exclusively on empirical experiences, today, with the highly developed molecular biological, high throughput methods, many molecular elements of their action have already been identified. However, fundamental questions remain to be answered, including bioavailability, effective doses, body concentrations, cross-reactivity, half-life and degradation, and synergistic effect of compounds as well as carefully designed clinical trials. The aim of the present review is to provide an overview of these plant-derived natural compounds that would support the use of medicinal plants (Figure 2). As a variety of compounds can influence inflammasome activation and function, we have focused on natural compounds that have been in long term use in traditional medicine; therefore, their safety and overall effect are mostly established. However, these compounds typically influence a multitude of pathways, and the exact molecular mechanisms of their beneficial actions are not completely clarified (Table 1).

Table 1: Natural compounds effecting NLRP3 inflammasome-mediated IL-1 production.
Figure 2: Chemical structure of natural compounds influencing NLRP3 inflammasome activation.

4. Natural Compounds Affecting NLRP3 Inflammasome Activation

4.1. Aloe vera

Aloe vera is a medical plant used traditionally in diverse therapeutic applications. The gel of Aloe vera has been reported to stimulate wound-healing and skin hydration, induce hematopoiesis, and possess antidiabetic, anticarcinogenic, antimicrobial, and antioxidant as well as anti-inflammatory activities. Over 75 active components have already been identified in Aloe vera leaf gels [94], and some of them have been implicated as immunomodulatory compounds based on animal studies. In a mouse sepsis model and in a human colorectal mucosa model, treatment with Aloe vera significantly inhibited the elevation of TNFα, IL-6, and IL-1β levels [95, 96]. Studying human THP-1 cells and human monocyte-derived macrophages, it was found that Aloe vera treatment significantly reduced LPS-induced IL-1β production [51]. Aloe vera inhibited the expression of pro-IL-1β, NLRP3, and caspase-1 as well as that of the P2X7 receptor in the LPS-induced primary macrophages. Furthermore, LPS-induced activation of signaling pathways, such as NF-κB, p38, JNK, and ERK, were inhibited by Aloe vera in these cells [51].

Aloe emodin is an anthraquinone, present naturally in Aloe leaves. It has been shown to promote natural killer cell activity and macrophage phagocytosis in tumor [97]. Emodin itself appears to have some protective effect in the inflammatory response. Recently, it was shown that emodin attenuated nigericin-, ATP-, and silica-induced IL-1β secretion from LPS-activated murine bone marrow-derived macrophages (BMDMs). It was also shown that mice treated intraperitoneally with emodin showed higher survival rates than control mice injected with LPS alone, indicating that emodin can ameliorate the severity of NLRP3 inflammasome-mediated disease symptoms in vivo [52]. However, further molecular details of the inhibitory effect are yet to be discovered.

4.2. Curcumin

Curcumin is a lipid soluble polyphenol, a yellow pigment isolated from the rhizomes of Curcuma longa (turmeric), but also found in other plants like ginger. It is widely used in food coloring and flavoring and it is also added to cosmetics. It has gained attention in recent years for its multiple pharmacological properties, being antioxidant, anti-inflammatory, and antimicrobial, as well as for its therapeutic potential in cancer, autoimmune, metabolic, pulmonary, cardiovascular, and neurological diseases (reviewed in [98]).

Brain ischemia is known to induce ER stress and inflammatory responses leading to neuronal damage [99, 100]. In a recent study, glucose deprivation or hypoxia was reported to strongly induce the production of glutamate and IL-1β in mouse hippocampus [53]. It was shown that pretreatment of the mouse hippocampus with curcumin reduced IL-1β production, and this effect was attenuated by 5′-AMP-activated protein kinase (AMPK) inhibitor, suggesting the possible involvement of AMPK. The authors also found that curcumin attenuated glutamate-induced phosphorylation of PERK and IRE1α; the transmembrane sensors of ER stress that mediate inflammatory signals. Moreover, using a neuroblastoma cell line, they showed that curcumin inhibited glutamate-induced ROS generation, as well as reduced glutamate-induced TXNIP expression. As a possible molecular mechanism, they found that, in mice hippocampus, glutamate stimulation increased NLRP3 expression and the cleaved form of caspase-1 enzyme, while curcumin attenuated NLRP3 and cleaved caspase-1 expression. The production of IL-6, a downstream target of IL-1β, was also inhibited by curcumin treatment. In addition, curcumin effectively attenuated mitochondrial function and prevented caspase-3 activation in hippocampus exposed to glutamate stimulation, effectively preventing glutamate-induced cell apoptosis. Furthermore, in rats, curcumin administration attenuated ischemic brain injury resulting from middle cerebral artery occlusion (MCAO). Based on these findings, curcumin activates AMPK that inhibits glutamate-induced ER stress and ROS production, thus inhibiting TXNIP-induced NLRP3 inflammasome activation and ultimately reducing IL-1β production in mouse hippocampus limiting brain injury.

Macrophages are popular models for the study of NLRP3 inflammasome activation. In another study performed on mouse macrophage cell line J774A.1 and peritoneal macrophages, curcumin was shown to strongly inhibit IL-1β secretion triggered by LPS plus nigericin, aluminum, ATP, or MSU [54]. Preincubation with curcumin prevented nigericin-induced intracellular potassium level decrease, attenuated lysosome damage and cathepsin B leakage, and blocked high mobility group box 1 (HMGB-1) release; needless to say, all of these are components that may induce NLRP3 inflammasome activation. In BMDMs, curcumin inhibited nigericin- or aluminum crystal-induced ROS production. The authors did not find obvious inhibitory effect of curcumin on JNK and p38 phosphorylation enhanced by nigericin treatment in the LPS-primed macrophages; however, they found that ERK1/2 phosphorylation was dramatically downregulated. In a mouse model of LPS-induced septic shock, administration of curcumin significantly decreased ROS level and cathepsin B leakage in peritoneal macrophages; additionally, peritoneal HMGB-1 and IL-1β concentrations were downregulated, resulting in a reduced LPS-induced splenomegaly. These data suggest that the observed reduction of secreted mature IL-1β by curcumin is primarily attributed to the inhibition of NLRP3 inflammasome activation.

4.3. EGCG

Epigallocatechin-3-gallate (EGCG) is the major bioactive polyphenol in green tea that has a well-documented antioxidant activity, as it functions as a free-radical scavenger. EGCG was reported to inhibit NFκB activation and the subsequent expression of several inflammatory molecules such as inducible nitric oxide synthase (iNOS), matrix metalloproteinases (MMPs), IL-6, and TNFα. Besides the anti-inflammatory role, EGCG was also thought to possess antitumor effect [101].

In unilateral ureteral obstruction mice model, renal inflammation has been linked to the activity of NLRP3 inflammasome and the overproduction of IL-1β. Furthermore, the role of NLRP3 inflammasome was proven in a variety of human nondiabetic and chronic kidney diseases [102]. It was reported that EGCG can prevent the development of lupus nephritis when administered to NZB/W F1 mice, the classical model of systemic lupus erythematosus [55]. These studies showed that EGCG treatment activated Nrf2 antioxidant pathway, induced the expression of Nrf2 downstream enzymes like NAD(P)H dehydrogenase (quinone) 1 (NQO1) and heme oxygenase 1 (HO-1), and reduced renal oxidative stress. Furthermore, EGCG inhibited renal NLRP3 inflammasome activity, and the expressions of NLRP3, caspase-1, and IL-1β were also reduced, possibly due to the EGCG-induced attenuation of NFκB pathway activity.

Very recently, the beneficial effect of EGCG was reported in a contrast-induced nephropathy (CIN) rat model [56]. CIN is a common iatrogenic cause of acute kidney injury (AKI) after exposure to iodinated contrast medium, characterized by oxidative stress and inflammation [103]. Similar to the previous study, they found that EGCG treatment reduced oxidative stress, and increased Nrf2 and HO-1 expression. They also found that EGCG reduced the elevated IL-1β secretion and NLRP3 protein expression. The molecular mechanisms of the observed results, however, were not studied.

4.4. Genipin

Genipin is a water-soluble bifunctional cross-linking reagent that was initially isolated from the Chinese medicinal plant Gardenia jasminoides (common name jasmine), and it has been used for centuries as a herbal medicine to protect the liver and gallbladder. It possesses antihypertensive, antibleeding, and antiswelling properties, in addition to exhibiting anti-inflammatory characteristics. Chemically, it is an aglycone, derived from an iridoid glycoside called geniposide that is enzymatically hydrolyzed to genipin by intestinal bacteria when administered per os [104]. Genipin was reported to inhibit mitochondrial uncoupling protein 2 (UCP2) as well as superoxide-activated UCP2-mediated proton leak occurring in a variety of diseases [105].

Recently, it was shown that overexpression of UCP2 caused a significant increase in NLRP3 expression in THP-1 cells, and this was significantly inhibited by the administration of genipin, while the levels of the adaptor protein ASC did not change [57]. Interestingly, genipin treatment attenuated IL-1β levels in LPS-primed cells treated with ATP; however, this effect was not observed in cells treated with nigericin. In addition, it was also shown that inhibition of ATP-mediated inflammasome activation by genipin does not alter the production of other proinflammatory cytokines such as IL-6 and TNFα.

In another recent study, in LPS-primed murine BMDMs, genipin dramatically inhibited IL-1β secretion of LPS-primed cells following ATP, nigericin, MSU crystals, or Listeria monocytogenes treatment [58]. Furthermore, genipin also inhibited the Salmonella typhimurium-induced secretion of IL-1β, which is mediated via the activation of NLRC4 inflammasome. Similar to the previous study, LPS-dependent TNFα secretion was not impaired by genipin. Importantly, genipin treatment did not inhibit the expression of pro-IL-1β, pro-caspase-1, or ASC proteins; however, it inhibited NLRP3-dependent ASC oligomerization in addition to IL-1β secretion and caspase-1 activation. In contrast to its inhibitory effect on NLRP3-mediated ASC oligomerization, genipin did not affect NLRC4-mediated formation of ASC speckles, while NLRC4-mediated caspase-1 activation was significantly diminished. These data indicate that the inhibitory effect of genipin on NLRC4 inflammasome activation is independent of ASC.

4.5. Ginseng

White ginseng is the naturally dried form of ginseng (Panax ginseng), while red ginseng is made by steaming and drying fresh ginseng root. Red ginseng has been used for centuries as an immune-modulator and has also been used as an adjuvant in the treatment of infectious and metabolic diseases. Korean red ginseng contains various active components, including saponins such as ginsenosides and nonsaponins such as polysaccharides, peptides, fatty acids, and mineral oils. Ginsenosides are the major active components of ginseng. They reduce the production of inflammatory cytokines by inhibiting NFκB signaling [106]. They also have amphiphilic nature and are able to intercalate into the plasma membrane and influence membrane fluidity and function.

It was shown that red ginseng extract (RGE) inhibited ATP-, nigericin-, and aluminum-induced IL-1β secretion in LPS-primed BMDMs and THP-1 cells and ameliorated lethality in LPS-induced septic shock model of mice [59]. Furthermore, RGE attenuated IL-1β secretion in dsDNA-transfected macrophages. Similar results were obtained for ginsenosides. Furthermore, it was also shown that RGE acted as an inhibitor of both NLRP3 and AIM2 inflammasome activations. It was also demonstrated that RGE attenuated the secretion of the active form of caspase-1 (p20).

It was previously reported that endogenous NO produced by iNOS inhibits NLRP3 inflammasome activation via the S-nitrosylation of NLRP3 protein [107, 108]. A recent study reported that ginsenosides negatively regulates LPS-induced septic shock in mice by a mechanism involving inhibition of iNOS expression and the subsequent NO production [60]. It was shown that ginsenosides reduced NO level, iNOS expression, and ROS level in peritoneal macrophages and BMDMs after LPS stimulation. They also found that ginsenoside treatment attenuated S-nitrosylation of NLRP3 protein, which resulted in increased IL-beta secretion in LPS-activated macrophages.

4.6. Mangiferin

Mangiferin is a water-soluble, natural polyphenol with a C-glycosylxanthone structure. The primary source of mangiferin is the mango tree (Mangifera indica); however, it is also present in some medicinal herbs, in Iris unguicularis, and in the honeybush, a popular herbal tea from South Africa. It possesses a wide spectrum of beneficial effects on health, being used as an analgesic, antidiabetic, antisclerotic, antimicrobial, and antiviral, as well as being praised for its anti-inflammatory effects. It has been shown to regulate AMPK activity, and, in a recent work, it was reported that, in human endothelial cells exposed to high glucose, mangiferin reduced IL-1β secretion [61]. Furthermore, mangiferin attenuated IRE1 phosphorylation and reduced ROS production, and it decreased TXNIP expression and inhibited ER stress. Moreover, a decrease in NLRP3 expression and IL-1β production was also demonstrated.

Very recently, the protective role of mangiferin was described in LPS plus D-galactosamine- (D-GalN-) induced acute liver injury [62]. The authors showed that mangiferin reduced IL-1β secretion and ROS production, and it also inhibited iNOS expression but induced Nrf2 and HO-1 expression. Furthermore, it attenuated NLRP3, ASC, and caspase-1 (p10) expression and the subsequent IL-1β production.

4.7. Propolis

Propolis is a resinous material, produced by bees (Apis mellifera L.) through the mixing of secretions and enzymes from their hypopharyngeal glands with the buds of plants and wax. A few hundred compounds have been detected in raw propolis, including polyphenols, terpenoids, steroids, sugar, and amino acids. Propolis composition is largely influenced by botanical origins and geographical location, as well as by collection season. One of the most known biological activities of propolis is related to its anti-inflammatory effect. Artepillin C is a simple phenol composed of a single ring with two prenyl groups (3,5-diprenyl-4-hydroxycinnamic acid) and is the major biologically active phenolic ingredient identified in green propolis derived from Southeast Brazil [109].

The role of artepillin C was studied on the oxidative metabolism of PMA-stimulated RAW264.7 macrophages [63]. It was shown that artepillin C significantly inhibited ROS release upon the NLRP3 activator nigericin treatment. It was also suggested that artepillin C significantly contributed to the modulation of chemokine-mediated inflammation, as it significantly downregulated the release of IL-1β, IL-12p40, and TNFα by LPS + IFNγ-treated RAW264.7 cells, whereas the synthesis of IL-1α and IL-6 was not affected. Besides nigericin-mediated IL-1β production, propolis also inhibited Legionella pneumophila-induced IL-1β cytokine secretion in LPS-primed BMDMs. This indicates that both NLRP3 and NLRC4 inflammasome functions may be regulated by propolis; however, further studies are required to clarify the detailed molecular mechanism of the observed results.

4.8. Quercetin

Quercetin, a kind of flavonoid found in a variety of vegetables, beverages, fruits, and herbs, exhibits anti-inflammatory and antioxidant properties. Quercetin was reported to reduce inflammation in visceral adipose tissue, primary human adipocytes, and the kidney of fructose-fed rats. It was also shown to prevent diabetic kidney injury in rats. However, the mechanisms of the action of quercetin were not clarified.

It has been described that quercetin attenuated fructose-induced hyperuricemia and renal dysfunction. In a study, using streptozotocin- (STZ-) induced diabetic nephropathy rat model leading to hyperuricemia and dyslipidemia, quercetin was found to block NLRP3 inflammasome activation [64]. It was shown that the STZ-induced expression of inflammasome components was restrained, and IL-1β secretion was reduced by quercetin treatment. Similar results were obtained studying inflammatory responses in fructose-induced hyperuricemia in rat [65]. They showed that fructose significantly elevated the expression of renal NLRP3, ASC, and caspase-1 expression, while quercetin treatment ameliorated the expression of these proteins. Based on their findings, it was suggested that fructose-mediated renal NLRP3 inflammasome activation and proinflammatory cytokine overproduction may be associated with the impaired cross talk between renal JAK2-STAT3 and PPAR-α signaling pathway that in turn regulate renal inflammation.

Furthermore, it was shown that quercetin markedly inhibited the overexpression of hepatic TXNIP, in addition to reducing the production of ROS and the activation of NLRP3 inflammasome, consequently resulting in decreased IL-1β secretion [66, 110]. They also showed that the decreased caspase-1 activity downregulated the caspase-1-dependent activation of SREBPs that are involved in fatty acid and cholesterol synthesis. They suggested that regulation of the TXNIP-NLRP3-SREBPs pathway by quercetin may partially mediate the alleviation of hepatic steatosis in these diabetic rats.

It was also shown that quercetin treatment regulated AMPK pathway activation, glutamine-glutamate cycle dysfunction, and TXNIP overexpression; moreover, it suppressed NFκB pathway, eventually leading to impaired NLRP3 inflammasome activation and IL-1β production in the hypothalamus of high fructose- (HF-) fed rats [67].

Using human umbilical vein endothelial cells, another group reported that quercetin suppressed palmitate- (PA-) induced IL-1β and IL-6 induction [68]. Downregulation of NLRP3 induction was probably partially mediated via the inhibition of ROS production and TXNIP expression; quercetin also inhibited IKKβ activation by attenuating its phosphorylation. Furthermore, quercetin treatment protected cells against PA insult and significantly reduced the number of apoptotic cells. Moreover, quercetin ameliorated ER stress-induced endothelial dysfunction through the activation of AMPK.

NLRP3 inflammasome is also recognized to have an important role in the spinal cord tissue after traumatic spinal cord injury (SCI), and targeting the NLRP3 inflammasome can inhibit neuroinflammation, thereby improving functional recovery in SCI rats [111].

Very recently, in a rat model of SCI, quercetin administration was shown to significantly improve functional recovery [69]. Histopathological changes of the spinal cord, such as congestion, edema, neutrophil infiltration, and structural disruption, were inhibited by quercetin administration. To formulate a molecular mechanism, the authors showed that quercetin administration significantly reduced inflammatory cytokine IL-1β, IL-18, and TNFα levels; it also reduced the NLRP3, ASC, and active caspase-1 protein expression and ROS production. However, further studies are needed to better characterize the mechanisms of action underlying the beneficial effects of quercetin in inflammation and immunity.

4.9. Resveratrol

Resveratrol is a polyphenol present in the skin of grapes and mulberry, commonly used in red wine production. The beneficial effects of resveratrol are thought to be mediated, in part, by its antioxidant and anti-inflammatory properties, exhibiting beneficial effects in several diseases [112]. Resveratrol exists as two isomers, cis- and trans-resveratrol. The cis isomer is thought to be produced naturally during grape fermentation as a result of isomerization of the trans isomer by yeast isomerases. Furthermore, cis-resveratrol can be obtained by exposure of the trans isomer to sunlight. Several studies have shown that trans-resveratrol exhibits a wide range of biological activities, including anti-inflammatory, antioxidant, anticarcinogenic, antiaging, antiplatelet aggregation, immune-modulatory, and chemoprevention effects. However, only few studies have been performed to examine the biological effects of the cis isomer. Studies on cis-resveratrol have demonstrated that it also possesses anticancer, antimicrobial, and antiplatelet aggregation activities.

One of the biological roles of resveratrol is to initiate the activation of sirtuin 1 (Sirt1) is a deacetylase that modifies and inactivates inflammatory genes. At high doses, resveratrol has been shown to activate AMPK; which is involved in the negative regulation of the NLRP3-inflammasome [113]. It was also shown that ionizing radiation-induced IL-1β secretion by human mesenchymal stem cells (MSCs), an effect that was effectively abrogated by pretreatment with resveratrol [70]. Radiation-induced increase in IL-1β occurs via the NLRP3 inflammasome activation; however, resveratrol treatment attenuated the expression of NLRP3. It was also demonstrated that resveratrol treatment upregulated the expression of Sirt1. In conclusion, it is suggested that Sirt1 inhibits NFκB transcriptional activity through deacetylation that in turn limits the transcription of NLRP3.

In another study, it was shown that cis-resveratrol pretreatment significantly inhibited IL-1β secretion in THP-1 cell culture supernatants; interestingly, cis-resveratrol induced IL-18 secretion under these conditions [71]. Accordingly, cis-resveratrol significantly reduced IL-1β mRNA expression; in contrast, cis-resveratrol used at the same concentration increased IL-18 mRNA expression. Furthermore, cis-resveratrol increased the mRNA and protein levels of NLRP1 and NLRP3, indicating that the inhibitory effect of cis-resveratrol on IL-1β secretion is not due to the downregulation of NLRP1, NLRP3, or ASC expression. Similar results were obtained on LPS-primed J774A.1 macrophages where resveratrol inhibited the ATP-induced IL-1β secretion; however, in this study, the authors did not find changes in the expression of NLRP3 [72], showing that the resveratrol did not inhibit the priming signal of NLRP3.

Huang et al. suggested that the inhibitory effect of cis-resveratrol on IL-1β secretion may be due to the reduced expression of purinergic receptor P2X7R and the ER stress marker GRP78, which leads to suppression of ROS production and reduced caspase-1 and caspase-4 activation. It was found that cis-resveratrol also inhibited cyclooxygenase- (COX-) 2 expression, which may be responsible for the observed decrease of PGE2 production. Furthermore, inhibition of pro-IL-1β and COX-2 expression may occur by downregulating the activation of the p38 MAPK pathway [71]. Importantly, in contrast to these observations, increased phosphorylation of p38 was detected in ATP-activated J774A.1 macrophages by Chang et al., while it did not significantly increase the phosphorylation levels of ERK1/2, and it reduced the phosphorylation levels of JNK1/2. The levels of mtDNA release into the cytosol were significantly reduced by resveratrol, indicating that there was less mitochondrial injury in resveratrol-treated cells [72] Furthermore, the authors also showed that resveratrol increased cellular cAMP level in J774A.1 macrophages, which acts as a negative regulator of inflammatory responses and inhibits NLRP3 inflammasome activation.

The effect of resveratrol on NLRP3 inflammasome was further proved by a study showing that four weeks of resveratrol administration inhibited the expression of NLRP3 inflammasome components, IL-1, IL-6, and TNFα, and in livers of HF-fed mice [73]. They also showed that the regulatory effects of resveratrol on NLRP3 inflammasome may come about through the combined effects of Sirt1 and Sirt6.

In a recent study [50], it was found that resveratrol treatment successfully suppressed the maturation of both IL-1β and caspase-1 in response to Pam3CSK4; a TLR1/2 agonist, plus various inducers (like nigericin, ATP, MSU, and silica) of the NLRP3-inflammasome. In mouse BMDMs, however, it did not affect the production of IL-1β mediated by the NLRC4-inflammasome (flagellin) or the AIM2-inflammasome (dsDNA). On a mouse model of acute gout, they indicated that resveratrol reduced the amount of mature IL-1β and the subsequent recruitment of neutrophils into the peritoneal cavities of mice after challenge with MSU crystals. These findings indicate that resveratrol suppresses the activation of the NLRP3-inflammasome both in vitro and in vivo. As a possible mechanism, they showed that resveratrol at a substantially higher dosage successfully suppressed mitochondrial ROS production. Furthermore, resveratrol treatment prevented the accumulation of acetylated α-tubulin; thus,inhibiting the proximate localization of ASC and NLRP3 in macrophages.

In a very recent publication [74], the authors showed that resveratrol prevented ATP-induced NLRP3 activation and IL-1β production in the BV2 cell line and in septic mice as well. They also found that resveratrol treatment reduced NLRP3 and IL-1β expression in the hippocampus of the mice, and they suggested that the protecting effect of resveratrol was mediated via the increased expression of Sirt1 in BV2 cells.

Another recent publication found that glucose-based peritoneal dialysis increased mitochondrial ROS production and subsequent IL-1β secretion through NLRP3 inflammasome in human peritoneal mesothelial cells (HPMC). As a mechanism for its action, they showed that resveratrol induced mitophagy/autophagy of the cells via AMPK activation and protected cells from ROS-induced NLRP3-mediated inflammatory injury [75].

4.10. Sulforaphane

Sulforaphane (SFN) is a natural compound present in cruciferous vegetables such as broccoli, cabbage, Brussel sprouts, mustard, and radish. Chemically, SFN is an isothiocyanate that is known to react with sulfhydryl groups and to modify proteins at cysteine residues. Sulforaphane is produced from the precursor glucoraphanin by the enzymatic activity of myrosinase, when the cell walls of the plant are damaged, for example, during chewing. SFN has been known as a cytoprotective agent for cancer prevention or treatment, and it also has an important role in cardiovascular, neurologic, and other diseases (reviewed in [114]). SFN is a known inducer of the Nrf2 antioxidant pathway, as it activates the Nrf2 transcription factor by reacting with cysteine residues of its repressor, Keap1 [115]. In addition, it also inhibits NFκB signaling [116].

It was shown that SFN inhibited IL-1β processing by NLRP1-, NLRP3-, NLRC4-, and AIM2- inflammasome complexes in mouse BMDMs [28]. It was also demonstrated that SFN inhibits the inflammasome in an Nrf2-independent manner, as SFN-mediated inhibition of NLRP3- and NLRC4-dependent IL-1β processing and secretion was not reversed in Nrf2-knockout BMDMs. When SFN was added directly to the cell lysates, it did not inhibit IL-1β processing, demonstrating that SFN does not directly inhibit the protease activity of caspase-1. The authors found that SFN-mediated inhibition of the inflammasomes is not affected by ROS modulation, and neither proteasome-dependent proteolysis nor de novo protein synthesis is required for SFN-mediated inhibition of the inflammasomes. In a peritonitis model of acute gout, SFN treatment significantly reduced MSU crystal-induced IL-1β production, demonstrating that SFN inhibits the NLRP3 inflammasome function in vivo. Nonetheless, the authors concluded that SFN inhibits multiple inflammasomes in vitro and in vivo by a mechanism independent of inflammasome priming and Nrf2 signaling; however, the exact molecular mechanism was not explored.

As SFN is able to penetrate the blood-brain barrier [117], it gained a considerable attention as a candidate for Alzheimer’s disease (AD) therapy. SFN was shown to protect the brain from Aβ-induced oxidative cell death via activation of Nrf2 signaling cascade [118]. As Aβ fibrils have been shown to activate NLRP3 inflammasome, the question arose whether SFN may regulate this mechanism. In a very recent study, it was shown that SFN significantly downregulated IL-1β production and NLRP3 expression in Aβ1–42 peptide-stimulated human THP-1 cells macrophages [76]. It was found that Aβ1–42 peptide-induced STAT-1 phosphorylation was significantly attenuated by SFN. The authors showed that SFN induced Nrf2 nuclear translocation, which was subsequently accompanied by an increase in HO-1 protein levels. Furthermore, Aβ1–42 peptide-induced IL-1β production was diminished by siRNA-mediated knockdown of Nrf2 or HO-1. They also found that the increased proinflammatory miRNA-146a level following Aβ1–42 treatment was significantly attenuated by SFN, whereas miRNA-125b and miRNA-155 levels were not changed. These are specific proinflammatory miRNAs that were reported to be increased in both the extracellular fluid and cerebrospinal fluid of AD patients. In conclusion, SFN can suppress Aβ1–42-induced caspase-1-dependent inflammasome activation, possibly through inhibiting STAT-1 phosphorylation and activation of the Nrf2/HO-1 signaling pathway.

Also very recently, another research group reported that oral administrations of SFN suppressed the saturated fatty acid-induced NLRP3 inflammasome activation in the liver of mice [77]. They found that SFN decreased the expression of ASC, caspase-1, and IL-1β levels; additionally, it inhibited the activity of caspase-1 enzyme in primary hepatocytes. It was also shown that SFN reduced the palmitate-induced ROS production by the mitochondria, implying that SFN prevented mitochondrial dysfunction, and this protecting mechanism was in part mediated by the activation of AMPK. They concluded that activation of AMPK and autophagy by SFN could protect from mitochondrial dysfunction induced by saturated fatty acids, resulting in a downregulation of fat-induced activation of the NLRP3 inflammasome.

5. NLRP3 Inflammasome and the Xenohormesis Hypothesis

As it was described in detail above, polyphenols like resveratrol, curcumin, EGCG, and quercetin are potent inhibitors of NLRP3 inflammasome-mediated IL-1β production, typically acting at more than one element of the involved pathways (Figure 3). However, it should be noted that these polyphenols have an even much broader biological effect, as they influence a variety of pathways [119], though not all are directly connected to the function of the NLRP3 inflammasome. Importantly, more than 8000 natural polyphenols have been described [120], providing a large library of compounds as potential inflammasome inhibitors. Many of these polyphenols (such as resveratrol and curcumin) are overproduced by stressed plants, triggering pathways mimicking the effect of caloric restriction. It has been proposed that organisms, from yeast to humans, consuming stressed plants could interpret the stress signal carried by such polyphenols as a potential risk of future limitation of food availability, and, in turn, adapting for the pursuit of longevity, a theory termed as Xenohormesis [121123]. Interestingly, the structurally unrelated resveratrol and curcumin can achieve this caloric restriction mimicking effect by activating AMPK and Sirt1 [124]. However, polyphenols are also known to have an antioxidant effect, activate glutathione S-transferases, and inhibit COX enzymes among many other effects [125, 126]. Interestingly, one of the most frequently used COX inhibitor is aspirin, a derivative of another stress-induced phytochemical, salicylic acid.

Figure 3: Molecular targets of natural compounds affecting NLRP3 inflammasome-mediated IL-1 production.

A major concern of polyphenol use in therapy is the bioavailability of these compounds. Nevertheless, typical dietary polyphenol intake is about 14 mg/kg/day, which is within the range of providing biologically active doses [127].

6. Concluding Remarks

Most of the time, inflammasome-mediated IL-1β production or caspase-mediated pyroptosis is beneficial for the host, as it protects from infection or prevents further damage. However, prolonged cytokine production, as in the case of sterile inflammation caused by endogenous danger signals, may lead to the development of autoinflammatory or metabolic diseases. Chronic inflammation compromises the host’s life quality and requires sustained pharmacological and surgical treatments. The paradigm of drug discovery in Western medicine is to develop highly selective compounds against individual druggable targets. Currently, the main treatment methods for these patients are targeting IL-1β. However, prolonged usage of drugs may induce different side effects; furthermore, some form of medications are very expensive, which limits their widespread use.

Besides the high expenses, another drawback of traditional drug design is that many of the promising compounds fail in the early or later stages of drug development. Traditional medicine uses many plant products to treat diseases; however, the exact mechanisms behind their use is still mostly lacking, partially as a consequence of the pleiotropic effect of the active compounds, as detailed in this review. Nevertheless, clarification of the molecular mechanism of action of such natural compounds, already used in traditional medicine for quite some time, will undoubtedly aid in the production of safe and cheap candidate medications to be used in the treatment of diseases, including those appearing as a consequence of NLRP3 inflammasome-mediated IL-1β overproduction.

Competing Interests

The authors declare no conflict of interests.

Acknowledgments

This work was supported by OTKA-K 109429. Szilvia Benkő is a receiver of Lajos Szodoray Postdoctoral Fellowship and János Bolyai Postdoctoral Fellowship.

References

  1. L. I. Romero, D.-N. Zhang, G. S. Herron, and M. A. Karasek, “Interleukin-1 induces major phenotypic changes in human skin microvascular endothelial cells,” Journal of Cellular Physiology, vol. 173, no. 1, pp. 84–92, 1997. View at Google Scholar · View at Scopus
  2. G. Meng, F. Zhang, I. Fuss, A. Kitani, and W. Strober, “A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses,” Immunity, vol. 30, no. 6, pp. 860–874, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Lasigliè, E. Traggiai, S. Federici et al., “Role of IL-1 beta in the development of human TH17 cells: lesson from NLPR3 mutated patients,” PLoS ONE, vol. 6, no. 5, Article ID e20014, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Schneider, F. Pitossi, D. Balschun, A. Wagner, A. Del Rey, and H. O. Besedovsky, “A neuromodulatory role of interleukin-1β in the hippocampus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7778–7783, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Gabay, G. Wolf, Y. Shavit, R. Yirmiya, and M. Tal, “Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury,” European Journal of Pain, vol. 15, no. 3, pp. 242–248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. A. del Rey, A. V. Apkarian, M. Martina, and H. O. Besedovsky, “Chronic neuropathic pain-like behavior and brain-borne IL-1β,” Annals of the New York Academy of Sciences, vol. 1262, no. 1, pp. 101–107, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Yirmiya and I. Goshen, “Immune modulation of learning, memory, neural plasticity and neurogenesis,” Brain, Behavior, and Immunity, vol. 25, no. 2, pp. 181–213, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. R. de Zoete, N. W. Palm, S. Zhu, and R. A. Flavell, “Inflammasomes,” Cold Spring Harbor Perspectives in Biology, vol. 6, no. 12, Article ID a016287, 2014. View at Publisher · View at Google Scholar
  9. M. Dagenais, A. Skeldon, and M. Saleh, “The inflammasome: in memory of Dr. Jurg Tschopp,” Cell Death and Differentiation, vol. 19, no. 1, pp. 5–12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. T.-D. Kanneganti, N. Özören, M. Body-Malapel et al., “Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3,” Nature, vol. 440, no. 7081, pp. 233–236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Mariathasan, D. S. Weiss, K. Newton et al., “Cryopyrin activates the inflammasome in response to toxins and ATP,” Nature, vol. 440, no. 7081, pp. 228–232, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. G. Hise, J. Tomalka, S. Ganesan et al., “An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen candida albicans,” Cell Host and Microbe, vol. 5, no. 5, pp. 487–497, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. T. Shio, S. C. Eisenbarth, M. Savaria et al., “Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases,” PLoS Pathogens, vol. 5, no. 8, article e1000559, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, “Gout-associated uric acid crystals activate the NALP3 inflammasome,” Nature, vol. 440, no. 7081, pp. 237–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Tschopp and K. Schroder, “NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?” Nature Reviews Immunology, vol. 10, no. 3, pp. 210–215, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Dostert, V. Pétrilli, R. Van Bruggen, C. Steele, B. T. Mossman, and J. Tschopp, “Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica,” Science, vol. 320, no. 5876, pp. 674–677, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Halle, V. Hornung, G. C. Petzold et al., “The NALP3 inflammasome is involved in the innate immune response to amyloid-β,” Nature Immunology, vol. 9, no. 8, pp. 857–865, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Pazár, H.-K. Ea, S. Narayan et al., “Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro,” Journal of Immunology, vol. 186, no. 4, pp. 2495–2502, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Duewell, H. Kono, K. J. Rayner et al., “NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals,” Nature, vol. 464, no. 7293, pp. 1357–1361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Benko, D. J. Philpott, and S. E. Girardin, “The microbial and danger signals that activate Nod-like receptors,” Cytokine, vol. 43, no. 3, pp. 368–373, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. F. G. Bauernfeind, G. Horvath, A. Stutz et al., “Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression,” Journal of Immunology, vol. 183, no. 2, pp. 787–791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. M. G. Ghonime, O. R. Shamaa, S. Das et al., “Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling and proteasome function,” Journal of Immunology, vol. 192, no. 8, pp. 3881–3888, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. Q. He, H. You, X.-M. Li, T.-H. Liu, P. Wang, and B.-E. Wang, “HMGB1 promotes the synthesis of pro-il-1β and pro-il-18 by activation of p38 MAPK and NF-kB through receptors for advanced glycation end-products in macrophages,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 4, pp. 1365–1370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Jin and R. A. Flavell, “Molecular mechanism of NLRP3 inflammasome activation,” Journal of Clinical Immunology, vol. 30, no. 5, pp. 628–631, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. S. M. Man and T.-D. Kanneganti, “Regulation of inflammasome activation,” Immunological Reviews, vol. 265, no. 1, pp. 6–21, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Shimada, T. R. Crother, J. Karlin et al., “Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis,” Immunity, vol. 36, no. 3, pp. 401–414, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. G.-S. Lee, N. Subramanian, A. I. Kim et al., “The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP,” Nature, vol. 491, no. 7427, pp. 123–127, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. A. J. Greaney, S. H. Leppla, and M. Moayeri, “Bacterial exotoxins and the inflammasome,” Frontiers in Immunology, vol. 6, article 570, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. E. I. Elliott and F. S. Sutterwala, “Initiation and perpetuation of NLRP3 inflammasome activation and assembly,” Immunological Reviews, vol. 265, no. 1, pp. 35–52, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Sokolovska, C. E. Becker, W. K. E. Ip et al., “Activation of caspase-1 by the NLRP3 inflammasome regulates the NADPH oxidase NOX2 to control phagosome function,” Nature Immunology, vol. 14, no. 6, pp. 543–553, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Kim, Y. Joe, S. O. Jeong et al., “Endoplasmic reticulum stress is sufficient for the induction of IL-1β production via activation of the NF-κB and inflammasome pathways,” Innate Immunity, vol. 20, no. 8, pp. 799–815, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. A. G. Lerner, J.-P. Upton, P. V. K. Praveen et al., “IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress,” Cell Metabolism, vol. 16, no. 2, pp. 250–264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Freigang, F. Ampenberger, G. Spohn et al., “Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis,” European Journal of Immunology, vol. 41, no. 7, pp. 2040–2051, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. G. M. Tannahill and L. A. J. O'Neill, “The emerging role of metabolic regulation in the functioning of Toll-like receptors and the NOD-like receptor Nlrp3,” FEBS Letters, vol. 585, no. 11, pp. 1568–1572, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Haneklaus and L. A. J. O'Neill, “NLRP3 at the interface of metabolism and inflammation,” Immunological Reviews, vol. 265, no. 1, pp. 53–62, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Bauernfeind, E. Bartok, A. Rieger, L. Franchi, G. Núñez, and V. Hornung, “Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome,” The Journal of Immunology, vol. 187, no. 2, pp. 613–617, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Perregaux and C. A. Gabel, “Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity,” The Journal of Biological Chemistry, vol. 269, no. 21, pp. 15195–15203, 1994. View at Google Scholar · View at Scopus
  38. J. M. Kahlenberg, K. C. Lundberg, S. B. Kertesy, Y. Qu, and G. R. Dubyak, “Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF-κB-driven protein synthesis,” Journal of Immunology, vol. 175, no. 11, pp. 7611–7622, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Muñoz-Planillo, P. Kuffa, G. Martínez-Colón, B. Smith, T. Rajendiran, and G. Núñez, “K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter,” Immunity, vol. 38, no. 6, pp. 1142–1153, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. V. Pétrilli, S. Papin, C. Dostert, A. Mayor, F. Martinon, and J. Tschopp, “Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration,” Cell Death and Differentiation, vol. 14, no. 9, pp. 1583–1589, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Murakami, J. Ockinger, J. Yu et al., “Critical role for calcium mobilization in activation of the NLRP3 inflammasome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 28, pp. 11282–11287, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Hornung, F. Bauernfeind, A. Halle et al., “Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization,” Nature Immunology, vol. 9, no. 8, pp. 847–856, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Dan Dunn, L. A. J. Alvarez, X. Zhang, and T. Soldati, “Reactive oxygen species and mitochondria: a nexus of cellular homeostasis,” Redox Biology, vol. 6, pp. 472–485, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. S. S. Iyer, Q. He, J. R. Janczy et al., “Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation,” Immunity, vol. 39, no. 2, pp. 311–323, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. X. Wang, W. Jiang, Y. Yan et al., “RNA viruses promote activation of the NLRP3 inflammasome through a RIP1-RIP3-DRP1 signaling pathway,” Nature Immunology, vol. 15, no. 12, pp. 1126–1133, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Ichinohe, T. Yamazaki, T. Koshiba, and Y. Yanagi, “Mitochondrial protein mitofusin 2 is required for NLRP3 inflammasome activation after RNA virus infection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 44, pp. 17963–17968, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Subramanian, K. Natarajan, M. R. Clatworthy, Z. Wang, and R. N. Germain, “The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation,” Cell, vol. 153, no. 2, pp. 348–361, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Y. Shaw, K. Tran, A. B. Castoreno et al., “Selective modulation of autophagy, innate immunity, and adaptive immunity by small molecules,” ACS Chemical Biology, vol. 8, no. 12, pp. 2724–2733, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Nakahira, J. A. Haspel, V. A. K. Rathinam et al., “Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome,” Nature Immunology, vol. 12, no. 3, pp. 222–230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Misawa, M. Takahama, T. Kozaki et al., “Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome,” Nature Immunology, vol. 14, no. 5, pp. 454–460, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. M. M. Budai, A. Varga, S. Milesz, J. Tőzsér, and S. Benkő, “Aloe vera downregulates LPS-induced inflammatory cytokine production and expression of NLRP3 inflammasome in human macrophages,” Molecular Immunology, vol. 56, no. 4, pp. 471–479, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. J.-W. Han, D.-W. Shim, W.-Y. Shin et al., “Anti-inflammatory effect of emodin via attenuation of NLRP3 inflammasome activation,” International Journal of Molecular Sciences, vol. 16, no. 4, pp. 8102–8109, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Li, J. Li, S. Li et al., “Curcumin attenuates glutamate neurotoxicity in the hippocampus by suppression of ER stress-associated TXNIP/NLRP3 inflammasome activation in a manner dependent on AMPK,” Toxicology and Applied Pharmacology, vol. 286, no. 1, pp. 53–63, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. Z. Gong, J. Zhou, H. Li et al., “Curcumin suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock,” Molecular Nutrition and Food Research, vol. 59, no. 11, pp. 2132–2142, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. P.-Y. Tsai, S.-M. Ka, J.-M. Chang et al., “Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation,” Free Radical Biology and Medicine, vol. 51, no. 3, pp. 744–754, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. Z. Gao, Y. Han, Y. Hu et al., “Targeting HO-1 by epigallocatechin-3-gallate reduces contrast-induced renal injury via anti-oxidative stress and anti-inflammation pathways,” PLOS ONE, vol. 11, no. 2, article e0149032, 2016. View at Publisher · View at Google Scholar
  57. V. Rajanbabu, L. Galam, J. Fukumoto et al., “Genipin suppresses NLRP3 inflammasome activation through uncoupling protein-2,” Cellular Immunology, vol. 297, no. 1, pp. 40–45, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. S.-X. Yu, C.-T. Du, W. Chen et al., “Genipin inhibits NLRP3 and NLRC4 inflammasome activation via autophagy suppression,” Scientific Reports, vol. 5, article 17935, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Kim, H. Ahn, B.-C. Han et al., “Korean red ginseng extracts inhibit NLRP3 and AIM2 inflammasome activation,” Immunology Letters, vol. 158, no. 1-2, pp. 143–150, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. S.-J. Yoon, J.-Y. Park, S. Choi et al., “Ginsenoside Rg3 regulates S-nitrosylation of the NLRP3 inflammasome via suppression of iNOS,” Biochemical and Biophysical Research Communications, vol. 463, no. 4, pp. 1184–1189, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Song, J. Li, F. Hou, X. Wang, and B. Liu, “Mangiferin inhibits endoplasmic reticulum stress-associated thioredoxin-interacting protein/NLRP3 inflammasome activation with regulation of AMPK in endothelial cells,” Metabolism, vol. 64, no. 3, pp. 428–437, 2015. View at Publisher · View at Google Scholar · View at Scopus
  62. C.-W. Pan, Z.-Z. Pan, J.-J. Hu et al., “Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation,” European Journal of Pharmacology, vol. 770, pp. 85–91, 2016. View at Publisher · View at Google Scholar · View at Scopus
  63. J. I. Hori, D. S. Zamboni, D. B. Carrão, G. H. Goldman, and A. A. Berretta, “The inhibition of inflammasome by Brazilian propolis (EPP-AF),” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 418508, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Wang, Y. Pan, Q.-Y. Zhang, F.-M. Wang, and L.-D. Kong, “Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation,” PLoS ONE, vol. 7, no. 6, Article ID e38285, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. Q.-H. Hu, X. Zhang, Y. Pan, Y.-C. Li, and L.-D. Kong, “Allopurinol, quercetin and rutin ameliorate renal NLRP3 inflammasome activation and lipid accumulation in fructose-fed rats,” Biochemical Pharmacology, vol. 84, no. 1, pp. 113–125, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. W. Wang, C. Wang, X.-Q. Ding et al., “Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats,” British Journal of Pharmacology, vol. 169, no. 6, pp. 1352–1371, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. Q.-Y. Zhang, Y. Pan, R. Wang et al., “Quercetin inhibits AMPK/TXNIP activation and reduces inflammatory lesions to improve insulin signaling defect in the hypothalamus of high fructose-fed rats,” Journal of Nutritional Biochemistry, vol. 25, no. 4, pp. 420–428, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Wu, X. Xu, Y. Li et al., “Quercetin, luteolin and epigallocatechin gallate alleviate TXNIP and NLRP3-mediated inflammation and apoptosis with regulation of AMPK in endothelial cells,” European Journal of Pharmacology, vol. 745, pp. 59–68, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. W. Jiang, Y. Huang, N. Han et al., “Quercetin suppresses NLRP3 inflammasome activation and attenuates histopathology in a rat model of spinal cord injury,” Spinal Cord, vol. 54, pp. 592–596, 2016. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Fu, Y. Wang, L. Du et al., “Resveratrol inhibits ionising irradiation-induced inflammation in MSCs by activating Sirt1 and limiting NLRP-3 inflammasome activation,” International Journal of Molecular Sciences, vol. 14, no. 7, pp. 14105–14118, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. T.-T. Huang, H.-C. Lai, Y.-B. Chen et al., “Cis-Resveratrol produces anti-inflammatory effects by inhibiting canonical and non-canonical inflammasomes in macrophages,” Innate Immunity, vol. 20, no. 7, pp. 735–750, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. Y.-P. Chang, S.-M. Ka, W.-H. Hsu et al., “Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy,” Journal of Cellular Physiology, vol. 230, no. 7, pp. 1567–1579, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. S. J. Yang and Y. Lim, “Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation,” Metabolism, vol. 63, no. 5, pp. 693–701, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. D.-M. Sui, Q. Xie, W.-J. Yi et al., “Resveratrol protects against sepsis-associated encephalopathy and inhibits the NLRP3/IL-1 β axis in microglia,” Mediators of Inflammation, vol. 2016, Article ID 1045657, 10 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Wu, X. Li, G. Zhu, Y. Zhang, M. He, and J. Zhang, “The role of Resveratrol-induced mitophagy/autophagy in peritoneal mesothelial cells inflammatory injury via NLRP3 inflammasome activation triggered by mitochondrial ROS,” Experimental Cell Research, vol. 341, no. 1, pp. 42–53, 2016. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. W. An, K. A. Jhang, S. Y. Woo, J. L. Kang, and Y. H. Chong, “Sulforaphane exerts its anti-inflammatory effect against amyloid-β peptide via STAT-1 dephosphorylation and activation of Nrf2/HO-1 cascade in human THP-1 macrophages,” Neurobiology of Aging, vol. 38, pp. 1–10, 2016. View at Publisher · View at Google Scholar
  77. G. Yang, H. E. Lee, and J. Y. Lee, “A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet,” Scientific Reports, vol. 6, Article ID 24399, 2016. View at Publisher · View at Google Scholar
  78. L. Franchi, R. Muñoz-Planillo, and G. Núñez, “Sensing and reacting to microbes through the inflammasomes,” Nature Immunology, vol. 13, no. 4, pp. 325–332, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. S. L. Cassel and F. S. Sutterwala, “Sterile inflammatory responses mediated by the NLRP3 inflammasome,” European Journal of Immunology, vol. 40, no. 3, pp. 607–611, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. M.-S. Tan, J.-T. Yu, T. Jiang, X.-C. Zhu, and L. Tan, “The NLRP3 inflammasome in alzheimer's disease,” Molecular Neurobiology, vol. 48, no. 3, pp. 875–882, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Gold and J. El Khoury, “β-amyloid, microglia, and the inflammasome in Alzheimer’s disease,” Seminars in Immunopathology, vol. 37, no. 6, pp. 607–611, 2015. View at Publisher · View at Google Scholar · View at Scopus
  82. P. M. Peeters, T. N. Perkins, E. F. M. Wouters, B. T. Mossman, and N. L. Reynaert, “Silica induces NLRP3 inflammasome activation in human lung epithelial cells,” Particle and Fibre Toxicology, vol. 10, no. 1, article 3, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Watanabe, O. Gaide, V. Pétrilli et al., “Activation of the IL-1β-processing inflammasome is involved in contact hypersensitivity,” Journal of Investigative Dermatology, vol. 127, no. 8, pp. 1956–1963, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. X. Dai, K. Sayama, M. Tohyama et al., “Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes,” Journal of Allergy and Clinical Immunology, vol. 127, no. 3, pp. 806–814, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Varga, M. M. Budai, S. Milesz, A. Bácsi, J. Tözsér, and S. Benkö, “Ragweed pollen extract intensifies lipopolysaccharide-induced priming of NLRP3 inflammasome in human macrophages,” Immunology, vol. 138, no. 4, pp. 392–401, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. B. Vandanmagsar, Y.-H. Youm, A. Ravussin et al., “The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance,” Nature Medicine, vol. 17, no. 2, pp. 179–189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Wen, D. Gris, Y. Lei et al., “Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling,” Nature Immunology, vol. 12, no. 5, pp. 408–415, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. L. Liang, X. Tan, Q. Zhou et al., “IL-1β triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome- dependent pathways is involved in ocular behçet's disease,” Investigative Ophthalmology and Visual Science, vol. 54, no. 1, pp. 402–414, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Rosengren, H. M. Hoffman, W. Bugbee, and D. L. Boyle, “Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium,” Annals of the Rheumatic Diseases, vol. 64, no. 5, pp. 708–714, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. J. M. Kahlenberg, “Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade,” Current Opinion in Rheumatology, vol. 28, no. 3, pp. 197–203, 2016. View at Publisher · View at Google Scholar · View at Scopus
  91. C.-H. Chien, M.-J. Lee, H.-C. Liou, H.-H. Liou, and W.-M. Fu, “Local immunosuppressive microenvironment enhances migration of melanoma cells to lungs in DJ-1 knockout mice,” PLoS ONE, vol. 10, no. 2, Article ID e0115827, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. C. Antonopoulos and G. R. Dubyak, “Chemotherapy engages multiple pathways leading to IL-1β production by myeloid leukocytes,” OncoImmunology, vol. 3, no. 1, Article ID e27499, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. E. Ozaki, M. Campbell, and S. L. Doyle, “Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives,” Journal of Inflammation Research, vol. 8, pp. 15–27, 2015. View at Publisher · View at Google Scholar · View at Scopus
  94. J. H. Hamman, “Composition and applications of Aloe vera leaf gel,” Molecules, vol. 13, no. 8, pp. 1599–1616, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. L. Langmead, R. J. Makins, and D. S. Rampton, “Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro,” Alimentary Pharmacology and Therapeutics, vol. 19, no. 5, pp. 521–527, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. N. Yun, C.-H. Lee, and S.-M. Lee, “Protective effect of Aloe vera on polymicrobial sepsis in mice,” Food and Chemical Toxicology, vol. 47, no. 6, pp. 1341–1348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. C. S. Yu, F. S. Yu, J. K. Chan et al., “Aloe-emodin affects the levels of cytokines and functions of leukocytes from Sprague-Dawley rats,” In Vivo, vol. 20, no. 4, pp. 505–509, 2006. View at Google Scholar
  98. M. Pulido-Moran, J. Moreno-Fernandez, C. Ramirez-Tortosa, and M. Ramirez-Tortosa, “Curcumin and health,” Molecules, vol. 21, no. 3, article E264, 2016. View at Publisher · View at Google Scholar
  99. Y.-F. Dong, L.-X. Wang, X. Huang et al., “Kir6.1 knockdown aggravates cerebral ischemia/reperfusion-induced neural injury in mice,” CNS Neuroscience and Therapeutics, vol. 19, no. 8, pp. 617–624, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. P. J. Maier, K. Zemoura, M. A. Acuña, G. E. Yévenes, H. U. Zeilhofer, and D. Benke, “Ischemia-like oxygen and glucose deprivation mediates down-regulation of cell surface γ-aminobutyric acidB receptors via the endoplasmic reticulum (ER) stress-induced transcription factor CCAAT/enhancer-binding protein (C/EBP)-homologous protein (CHOP),” The Journal of Biological Chemistry, vol. 289, no. 18, pp. 12896–12907, 2014. View at Publisher · View at Google Scholar · View at Scopus
  101. H.-Y. Shin, S.-H. Kim, H.-J. Jeong et al., “Epigallocatechin-3-gallate inhibits secretion of TNF-α, IL-6 and IL-8 through the attenuation of ERK and NF-κB in HMC-1 cells,” International Archives of Allergy and Immunology, vol. 142, no. 4, pp. 335–344, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. W. P. Pulskens, L. M. Butter, G. J. Teske et al., “Nlrp3 prevents early renal interstitial edema and vascular permeability in unilateral ureteral obstruction,” PLoS ONE, vol. 9, no. 1, Article ID e85775, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Kamath and C. A. Roobottom, “Hyperdense pericardial effusion in dermatomyositis and contrast induced nephropathy,” Emergency Radiology, vol. 11, no. 3, pp. 177–179, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. T. Akao, K. Kobashi, and M. Aburada, “Enzymic studies on the animal and intestinal bacterial metabolism of geniposide,” Biological and Pharmaceutical Bulletin, vol. 17, no. 12, pp. 1573–1576, 1994. View at Publisher · View at Google Scholar · View at Scopus
  105. R. Wang, K. C. MoYung, M. H. Zhang, and K. Poon, “UCP2- and non-UCP2-mediated electric current in eukaryotic cells exhibits different properties,” Environmental Science and Pollution Research, vol. 22, no. 24, pp. 19618–19631, 2015. View at Publisher · View at Google Scholar · View at Scopus
  106. J.-M. Lü, Q. Yao, and C. Chen, “Ginseng compounds: an update on their molecular mechanisms and medical applications,” Current Vascular Pharmacology, vol. 7, no. 3, pp. 293–302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. E. Hernandez-Cuellar, K. Tsuchiya, H. Hara et al., “Cutting edge: nitric oxide inhibits the NLRP3 inflammasome,” The Journal of Immunology, vol. 189, no. 11, pp. 5113–5117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. B. B. Mishra, V. A. K. Rathinam, G. W. Martens et al., “Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1β,” Nature Immunology, vol. 14, no. 1, pp. 52–60, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. T. Matsuno, S.-K. Jung, Y. Matsumoto, M. Saito, and J. Morikawa, “Preferential cytotoxicity to tumor cells of 3,5-diprenyl-4-hydroxycinnamic acid (artepillin C) isolated from propolis,” Anticancer Research, vol. 17, no. 5A, pp. 3565–3568, 1997. View at Google Scholar · View at Scopus
  110. X. Zhang, J.-H. Zhang, X.-Y. Chen et al., “Reactive oxygen species-induced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation,” Antioxidants and Redox Signaling, vol. 22, no. 10, pp. 848–870, 2015. View at Publisher · View at Google Scholar · View at Scopus
  111. A. Zendedel, S. Johann, S. Mehrabi et al., “Activation and regulation of NLRP3 inflammasome by intrathecal application of SDF-1a in a spinal cord injury model,” Molecular Neurobiology, vol. 53, no. 5, pp. 3063–3075, 2016. View at Publisher · View at Google Scholar · View at Scopus
  112. H. Inoue and R. Nakata, “Resveratrol targets in inflammation,” Endocrine, Metabolic and Immune Disorders—Drug Targets, vol. 15, no. 3, pp. 186–195, 2015. View at Publisher · View at Google Scholar · View at Scopus
  113. S. S. Kulkarni and C. Cantó, “The molecular targets of resveratrol,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1852, no. 6, pp. 1114–1123, 2015. View at Publisher · View at Google Scholar · View at Scopus
  114. C. A. Houghton, R. G. Fassett, and J. S. Coombes, “Sulforaphane: translational research from laboratory bench to clinic,” Nutrition Reviews, vol. 71, no. 11, pp. 709–726, 2013. View at Publisher · View at Google Scholar · View at Scopus
  115. A. T. Dinkova-Kostova, W. D. Holtzclaw, R. N. Cole et al., “Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11908–11913, 2002. View at Publisher · View at Google Scholar · View at Scopus
  116. E. Heiss, C. Herhaus, K. Klimo, H. Bartsch, and C. Gerhäuser, “Nuclear factor κB is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms,” The Journal of Biological Chemistry, vol. 276, no. 34, pp. 32008–32015, 2001. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Alfieri, S. Srivastava, R. C. M. Siow et al., “Sulforaphane preconditioning of the Nrf2/HO-1 defense pathway protects the cerebral vasculature against blood-brain barrier disruption and neurological deficits in stroke,” Free Radical Biology and Medicine, vol. 65, pp. 1012–1022, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. C. Lee, G. H. Park, S.-R. Lee, and J.-H. Jang, “Attenuation of β -amyloid-induced oxidative cell death by sulforaphane via activation of NF-E2-related factor 2,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 313510, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  119. E. Barrajón-Catalán, M. Herranz-López, J. Joven et al., “Molecular promiscuity of plant polyphenols in the management of age-related diseases: far beyond their antioxidant properties,” Advances in Experimental Medicine and Biology, vol. 824, pp. 141–159, 2014. View at Publisher · View at Google Scholar · View at Scopus
  120. L. Bravo, “Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance,” Nutrition Reviews, vol. 56, no. 11, pp. 317–333, 1998. View at Google Scholar
  121. D. W. Lamming, J. G. Wood, and D. A. Sinclair, “Small molecules that regulate lifespan: evidence for xenohormesis,” Molecular Microbiology, vol. 53, no. 4, pp. 1003–1009, 2004. View at Publisher · View at Google Scholar · View at Scopus
  122. K. T. Howitz and D. A. Sinclair, “Xenohormesis: sensing the chemical cues of other species,” Cell, vol. 133, no. 3, pp. 387–391, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. P. L. Hooper, P. L. Hooper, M. Tytell, and L. Vígh, “Xenohormesis: health benefits from an eon of plant stress response evolution,” Cell Stress and Chaperones, vol. 15, no. 6, pp. 761–770, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. B. L. Queen and T. O. Tollefsbol, “Polyphenols and aging,” Current Aging Science, vol. 3, no. 1, pp. 34–42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. J. A. Baur and D. A. Sinclair, “Therapeutic potential of resveratrol: the in vivo evidence,” Nature Reviews Drug Discovery, vol. 5, no. 6, pp. 493–506, 2006. View at Publisher · View at Google Scholar · View at Scopus
  126. R. A. Sharma, A. J. Gescher, and W. P. Steward, “Curcumin: the story so far,” European Journal of Cancer, vol. 41, no. 13, pp. 1955–1968, 2005. View at Publisher · View at Google Scholar · View at Scopus
  127. K. Milton, “Micronutrient intakes of wild primates: are humans different?” Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology, vol. 136, no. 1, pp. 47–59, 2003. View at Publisher · View at Google Scholar · View at Scopus